(SEATTLE), February 4, 2020-- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore lost vision in patients with corneal diseases by regenerating corneal tissue.
Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases
by Diane Hunt on 2/6/20 4:49 PM News
Learn More
Follow Us
